Proteomics International Laboratories Ltd

ASX:PIQ Stock Report

Market Cap: AU$83.8m

Proteomics International Laboratories Management

Management criteria checks 3/4

Proteomics International Laboratories' CEO is Richard Lipscombe, appointed in Jan 2001, has a tenure of 23.92 years. total yearly compensation is A$415.35K, comprised of 87.9% salary and 12.1% bonuses, including company stock and options. directly owns 12.53% of the company’s shares, worth A$10.51M. The average tenure of the management team and the board of directors is 2.9 years and 2.7 years respectively.

Key information

Richard Lipscombe

Chief executive officer

AU$415.3k

Total compensation

CEO salary percentage87.9%
CEO tenure23.9yrs
CEO ownership12.5%
Management average tenure2.9yrs
Board average tenure2.7yrs

Recent management updates

Most Shareholders Will Probably Find That The CEO Compensation For Proteomics International Laboratories Limited (ASX:PIQ) Is Reasonable

Nov 16
Most Shareholders Will Probably Find That The CEO Compensation For Proteomics International Laboratories Limited (ASX:PIQ) Is Reasonable

Here's Why We Think Proteomics International Laboratories Limited's (ASX:PIQ) CEO Compensation Looks Fair for the time being

Nov 17
Here's Why We Think Proteomics International Laboratories Limited's (ASX:PIQ) CEO Compensation Looks Fair for the time being

Recent updates

Most Shareholders Will Probably Find That The CEO Compensation For Proteomics International Laboratories Limited (ASX:PIQ) Is Reasonable

Nov 16
Most Shareholders Will Probably Find That The CEO Compensation For Proteomics International Laboratories Limited (ASX:PIQ) Is Reasonable

Calculating The Fair Value Of Proteomics International Laboratories Limited (ASX:PIQ)

Sep 29
Calculating The Fair Value Of Proteomics International Laboratories Limited (ASX:PIQ)

We're Hopeful That Proteomics International Laboratories (ASX:PIQ) Will Use Its Cash Wisely

May 10
We're Hopeful That Proteomics International Laboratories (ASX:PIQ) Will Use Its Cash Wisely

Here's Why We Think Proteomics International Laboratories Limited's (ASX:PIQ) CEO Compensation Looks Fair for the time being

Nov 17
Here's Why We Think Proteomics International Laboratories Limited's (ASX:PIQ) CEO Compensation Looks Fair for the time being

Is Proteomics International Laboratories (ASX:PIQ) In A Good Position To Invest In Growth?

Aug 09
Is Proteomics International Laboratories (ASX:PIQ) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Richard Lipscombe's remuneration changed compared to Proteomics International Laboratories's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$415kAU$365k

-AU$6m

Mar 31 2024n/an/a

-AU$6m

Dec 31 2023n/an/a

-AU$6m

Sep 30 2023n/an/a

-AU$6m

Jun 30 2023AU$442kAU$350k

-AU$6m

Mar 31 2023n/an/a

-AU$6m

Dec 31 2022n/an/a

-AU$6m

Sep 30 2022n/an/a

-AU$5m

Jun 30 2022AU$330kAU$265k

-AU$5m

Mar 31 2022n/an/a

-AU$5m

Dec 31 2021n/an/a

-AU$4m

Sep 30 2021n/an/a

-AU$4m

Jun 30 2021AU$298kAU$250k

-AU$3m

Mar 31 2021n/an/a

-AU$3m

Dec 31 2020n/an/a

-AU$2m

Sep 30 2020n/an/a

-AU$2m

Jun 30 2020AU$299kAU$250k

-AU$2m

Mar 31 2020n/an/a

-AU$2m

Dec 31 2019n/an/a

-AU$2m

Sep 30 2019n/an/a

-AU$2m

Jun 30 2019AU$207kAU$185k

-AU$2m

Mar 31 2019n/an/a

-AU$2m

Dec 31 2018n/an/a

-AU$2m

Sep 30 2018n/an/a

-AU$2m

Jun 30 2018AU$156kAU$170k

-AU$1m

Compensation vs Market: Richard's total compensation ($USD259.77K) is about average for companies of similar size in the Australian market ($USD291.73K).

Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.

CEO

Richard Lipscombe

23.9yrs

Tenure

AU$415,346

Compensation

Dr. Richard John Lipscombe, Ph D (London), MA (Oxford), co-founded Proteomics International Laboratories Limited in 2001 and serves as its Managing Director and Director since June 09, 2014. Mr. Lipscombe...

Leadership Team

NamePositionTenureCompensationOwnership
Richard Lipscombe
Co-Founder23.9yrsAU$415.35k12.53%
A$ 10.5m
Jacqueline Gray
CFO & Head of Corporate Development3.4yrsAU$445.81k0.049%
A$ 41.0k
John Morrison
Head of Business Developmentno datano datano data
Scott Bringans
Head of Research2.9yrsno datano data
Pearl Tan
Head of Product Development2.4yrsno datano data
Kirsten Peters
Head of Clinical Studiesno datano datano data
Phillip Prather
Chief Commercial Officerless than a yearno datano data
Karen Logan
Company Secretaryno datano datano data

2.9yrs

Average Tenure

Experienced Management: PIQ's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Richard Lipscombe
Co-Founder10.5yrsAU$415.35k12.53%
A$ 10.5m
Neville Gardiner
Independent Non-Executive Director3.1yrsAU$87.37k0.090%
A$ 75.3k
Eleuterio Ferrannini
Member of Clinical Advisory Board2.7yrsno datano data
Paul House
Independent Non-Executive Director7.1yrsAU$52.45k0.79%
A$ 663.4k
Hope Warshaw
Member of Clinical Advisory Boardno datano datano data
Tim Davis
Member of Clinical Advisory Board2.7yrsno datano data
Alexander Turchin
Member of Clinical Advisory Board2.7yrsno datano data
Davida Kruger
Member of Clinical Advisory Boardno datano datano data
Michael Shanik
Member of Clinical Advisory Board2.7yrsno datano data
Merlin Thomas
Member of Clinical Advisory Board2.7yrsno datano data
Neil Sholnik
Member of Clinical Advisory Boardno datano datano data
James Williams
Independent Non- Executive Chairmanless than a yearno datano data

2.7yrs

Average Tenure

Experienced Board: PIQ's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 23:28
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Proteomics International Laboratories Ltd is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Iain WilkieMorgans Financial Limited